15 Feb AbnomX Announces the Release of Antibody-Extractor™ 11 with HumanizerAI

Posted at 16:04h in News by

AbnomX Announces the Release of Antibody-Extractor™ 11 with HumanizerAI

Belgium, February 15, 2025 – AbnomX unveils Antibody-Extractor™ 11, a groundbreaking upgrade to its Antibody-Extractor™ (AE) platform, integrating cutting-edge technology to enhance antibody design, humanization, and analysis.

At the core of this release is HumanizerAI, our in-house AI model that optimizes therapeutic antibodies by minimizing immunogenicity while preserving critical binding properties. By leveraging vast human antibody sequence datasets and our deep scientific expertise in antibody engineering, HumanizerAI streamlines the humanization process, making it faster, more precise, and highly reliable.

“HumanizerAI represents a major leap forward in antibody engineering,” said Khalil El Mazouari, PhD, Founder & CEO of AbnomX. “By combining AI with our deep expertise in antibody engineering, we are providing researchers with a powerful tool to accelerate immunotherapeutic development and reduce risks associated with immunogenicity.”

The update introduces several key enhancements:

  • MotifFinder: A novel algorithm that enhances sequence analysis based on AbnomX’s deep expertise in antibody and nanobody engineering, providing researchers with critical insights into stability, affinity, and manufacturability.
  • Advanced Annotation Algorithms: More precise sequence analysis, enabling better decision-making in antibody engineering.
  • Performance Optimizations: Faster processing speeds for large-scale antibody discovery and optimization.

“These innovations reflect our commitment to providing researchers with smart, science-driven tools that enhance efficiency and reliability in antibody development,” added El Mazouari.

The upgraded Antibody-Extractor™ 11 platform is available now. Researchers and biotech companies can explore these new capabilities by visiting www.abnomx.com or contacting info@abnomx.com.

About AbnomX

AbnomX develops state-of-the-art software solutions for in-silico antibody discovery, engineering, and analysis. The company’s Antibody-Extractor™ platform is trusted by pharmaceutical companies and research institutions worldwide to accelerate therapeutic discovery and development.

📍 AbnomX bv, Ghent, Belgium
📧 info@abnomx.com | 🌐 www.abnomx.com

 

Print page
1 Like